_256_384.jpg)
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
The aim is to create new genomics solutions that could combat cancer and advance market access
A veteran in cell therapy and oncology commercialisation
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Nearly 6,000 patients have been treated with the drug since 2017
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
Subscribe To Our Newsletter & Stay Updated
